Cullinan Oncology Inc
NASDAQ:CGEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Talenom Oyj
LSE:0RQI
|
FI |
|
W
|
Watches of Switzerland Group PLC
OTC:WOSGF
|
UK |
|
Kingston Financial Group Ltd
HKEX:1031
|
HK |
|
T
|
Tianli Holdings Group Ltd
HKEX:117
|
HK |
|
N
|
NTT UD REIT Investment Corp
TSE:8956
|
JP |
|
NNK Group Ltd
HKEX:3773
|
CN |
|
3SBio Inc
HKEX:1530
|
CN |
|
Daiseki Co Ltd
TSE:9793
|
JP |
|
F
|
Fast Accounting Co Ltd
TSE:5588
|
JP |
Cullinan Oncology Inc
EPS (Diluted)
Cullinan Oncology Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cullinan Oncology Inc
NASDAQ:CGEM
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Cullinan Oncology Inc
Glance View
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.
See Also
What is Cullinan Oncology Inc's EPS (Diluted)?
EPS (Diluted)
-3.1
USD
Based on the financial report for Dec 31, 2024, Cullinan Oncology Inc's EPS (Diluted) amounts to -3.1 USD.
What is Cullinan Oncology Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-44%
Over the last year, the EPS (Diluted) growth was 16%. The average annual EPS (Diluted) growth rates for Cullinan Oncology Inc have been -27% over the past three years , -44% over the past five years .
